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Through collaboration and innovation, UNLV researchers are changing the way we think about the brain.
PORTRAITS BY JOSH HAWKINS
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Patterns of Activity
A
s a 19-year-old education major, Rochelle 
Hines’ career ambition was to work with 
schoolchildren who have special needs. 
Then she enrolled in an elective course called 
“Brain and Behavior.”
“I was captivated,” Hines says. “By the sec-
ond week of this class, I had changed my major 
and started working in the lab of my professor.”
The undergraduate research experience that 
followed enabled Hines to use various advanced 
technologies—electron microscopy among 
them—to gain a thrilling view of cerebral struc-
tures at the molecular level. From there, she re-
calls, she went on to explore sites of communica-
tion between brain cells, called synapses, falling 
“in love with their incredible intricacy.
“I became focused on wanting to understand 
how we build billions of these complex structures 
so reliably during normal development, and how 
a failure in this process may lead to developmen-
tal disorders like those that I observed working 
with children with special needs.”
Her early fascination with neuroscience has 
spawned a career rich in research. Today, Ro-
chelle Hines, along with her husband and col-
laborator Dustin Hines, is rapidly expanding our 
understanding of how, for better or worse, neu-
ronal activity patterns guide human behavior 
and ultimately contribute to pathology.
“Patterned activity in the brain is achieved 
through a balanced relationship between ‘on’ 
signals originating from excitatory cells and ‘off’ 
signals from inhibitory cells that act to modulate 
the activity of the excitatory cells,” she says. Her 
focus, she adds, tends toward the inhibitory 
cells, cellular “dimmer switches” that finely tune 
levels of excitation in the brain.
“Rochelle and I have a common thread, in 
that we both study cells in the brain that modu-
late brain activity patterns,” says Dustin, noting 
that he focuses more on the brain’s abundant glial 
cells, which surround neurons and provide sup-
port for and insulation between them.
The couple, who recently moved to Las Vegas 
together to continue their research in UNLV’s 
psychology department, shares an interest in this 
area of neuroscience for a number of reasons. 
“The subject of modulatory cells has been at-
tractive to us, as many studies are now pointing 
to this area as the most likely avenue for thera-
peutic advancement,” says Dustin, noting that 
pharmaceutical companies have been interested 
in his research. “We also enjoy working in these 
areas because, to date, they are largely under-
studied in neuroscience. So it’s exciting to work 
on topics where there are a lot of new discover-
ies and advancements to be made.”
The two researchers, who met early in their 
careers, work synergistically. Both explore the 
functioning of these modulatory systems in the 
brain, but each has a specialty area. Rochelle uses a 
molecular and cellular approach to focus on 
interneurons, also called “relay neurons,” cells that 
modulate communication between other neurons. 
Dustin’s work with glial cells, specifically astrocytes 
and microglia, involves a cellular physiological and 
behavioral approach to understand how glia 
modulate neuronal communication.
His research has implications for degenera-
tive maladies such as depression and stroke. For 
example, one of his studies examined how the 
chemicals activated in sleep deprivation may be 
used to help diminish depression. His research 
team used an animal model to examine how a 
certain compound that affects adenosine recep-
tors in the brain mimics sleep deprivation and 
improves mood and behavior. 
He believes glial cells have been largely over-
looked in brain research and provide an oasis for 
novel therapeutics. 
“The tools that were needed to study glial 
cells were not available early on in neuroscience 
research,” he says. “After World War II, many elec-
trical technologies used to detect submarines, like 
oscilloscopes, drove the research; consequently, 
the electrical properties of neurons became the 
focus of the field. In the late 1980s, the develop-
ment of new microscopes and genetic tools al-
lowed us to see how glial cells contribute to brain 
function by modulating neurons.” 
Rochelle’s research, meanwhile, examines 
how interneurons and inhibitory synapses 
affect neurodevelopmental disorders such as 
autism and schizophrenia. By investigating the 
activities of inhibitory cells in the brain—those 
“dimmer-switch” cells that finely tune 
JJeff Kinney chose to join the UNLV psychology faculty in 2007 for many reasons, but the one that clinched the deal was the opportunity to build out the neuroscience area.“The prospect of building a program from the ground up was far more appealing to me than joining an already established group,” says Kinney. “For me, carving out something new had great appeal.”Today, Kinney’s hopes—and his efforts in his first several years here— are coming to fruition. In the last year, he led a UNLV research team that joined with the Cleveland Clinic 
Lou Ruvo Center for Brain Health to obtain an $11.1 million grant from the National Institutes 
of Health for advanced study of both Parkinson’s and Alzheimer’s diseases. Additionally, 
the department now offers a Ph.D. area of emphasis in neuroscience, with plans to offer a 
stand-alone neuroscience doctorate soon. The department also recently launched a 
neuroscience minor, in which more than 100 undergraduates are currently enrolled.
“And now the department is approaching a critical mass of faculty in neuroscience, and 
faculty from other departments are collaborating with us as well,” he says. “This will enable 
us to begin building a center of excellence in neuroscience that will dramatically help with 
securing research funding in the form of collaborative and individual grants.”  
One of the keys to the successful acquisition of research dollars, he notes, is the inclusion 
of collaborators, both on and off campus. Kinney and his team are working with several 
UNLV faculty members studying myriad topics. The following profiles offer a glimpse into 
the growing neuroscience research being conducted on the UNLV campus.
PARTNERS IN MIND Husband-and-wife team 
Dustin and Rochelle Hines research brain cells 
in their quest for solutions to degenerative 
diseases and developmental disorders.
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levels of excitation—she seeks to learn more 
about the development of signaling in the 
nervous system. 
“Excitatory signaling can be thought of as a 
typical light switch, either fully on or fully off,” 
she says, adding that inhibitory signaling modu-
lates this activity, allowing for subtler variations 
of brain activity. 
Like her husband, Rochelle chose to study a re-
search area that has abundant potential for discovery. 
“The role of inhibitory signaling is becoming 
increasingly apparent, and much of it is based on 
the symptoms associated with these disorders as 
well as studies in postmortem tissue from human 
subjects with these disorders,” she says. 
She recently authored an article describing a 
study of inhibitory receptors in the brain and 
how certain inhibitory synapses might contrib-
ute to the symptoms of schizophrenia.
“These receptors are the target for many 
drugs that are in wide clinical use, including an-
esthetics and anti-anxiety and sleep drugs, so we 
know that they are a powerful target,” she says. 
Her work has also garnered the interest of phar-
maceutical companies.
The couple has more than 50 scholarly jour-
nal articles between them. By the end of the year, 
they expect to submit their first jointly authored 
article emanating from their UNLV research. It 
will focus on how the brain regulates sleep.  
 —Sue DiBella
Smoking and Schizophrenia
Y
ou might be surprised to learn that the 
smoking rate for schizophrenic patients is 
45 to 88 percent higher than the general 
population’s, according to “Co-Morbidity of 
Smoking in Patients With Psychiatric and Sub-
stance Use Disorders,” published in the Ameri-
can Journal on Addictions. And if you wonder 
what the underlying cause of such a pervasive 
habit might be, you’re not alone.  
Xiangning Chen and Jingchun Chen of the 
UNLV Nevada Institute of Personalized Medicine 
(NIPM) are looking to genetics for the answer. 
“Genetics actually influences everything we are 
and do,” Xiangning Chen says. “Genetics defines 
your potential or capacity, and how you reach that 
capacity depends on the environment you’re in.” 
People with schizophrenia can experience 
delusions, hallucinations, dissociations from 
reality, abnormal social behavior, erratic speech 
and behavior, and the inability to focus and 
recall information. Although environmental 
factors may contribute to the development of 
schizophrenia, the disorder has been linked 
to specific genetic variants that predispose a 
person to developing the condition.   
“Researchers have performed a lot of twin 
studies and family studies with respect to schizo-
phrenia,” Jingchun Chen says. “The results show 
time and again that the more overlap people have 
in their genetic makeup, the greater their chances 
are for developing this disorder. For instance, if 
one twin sibling has schizophrenia, the other has 
a 50 percent chance of developing it as well. So 
there’s clearly a genetic component.”
Previous research has noted a strong corre-
lation between heavy smoking and schizophre-
nia. A 2011 finding in the journal Psychiatric 
Services, for example, concluded that the “prev-
alence of smoking has remained alarmingly 
high among individuals with schizophrenia 
and bipolar disorder in routine psychiatric set-
tings.” Although there is some dispute among 
researchers as to why, the most commonly cit-
ed explanation is that patients are attempting 
to “self-medicate.” In short, researchers have 
concluded schizophrenic patients smoke be-
cause it makes them feel better.
Xiangning Chen and Jingchun Chen 
wondered whether genetics might play a role in 
creating this analgesic effect.
Supported in part by separate grants from 
the National Institutes of Health, Xiangning 
Chen and Jingchun Chen examined genes 
associated with both schizophrenia and smoking 
to determine whether the disorder and nicotine 
dependence might be linked. Using sophisticated 
analytic techniques as well as data on the genetic 
components involved in the general population’s 
smoking behavior, the two discovered that while 
there was likely a genetic predisposition to 
smoking in schizophrenics, the cause of 
schizophrenic patients’ excessive tobacco use 
was not entirely due to nicotine dependence or 
addiction, as is often the case with smokers in 
the general population.  
“Schizophrenic patients have some unique be-
havioral factors that cause them to smoke, and 
smoke quite a bit,” says Xiangning Chen, a profes-
sor in both UNLV’s Department of Psychology and 
NIPM. “One of the challenges for schizophrenic 
patients is that they cannot remember things ac-
curately, follow their thoughts easily, or concen-
trate effectively. Therefore, they use cigarettes to 
help them cope and overcome some of the symp-
toms caused by the disorder, as one effect of nico-
tine on humans is to improve cognitive function.”
Although schizophrenic patients are smoking 
for reasons that extend beyond what their ge-
nomes might predispose them to, the discovery of 
genetic liability between the schizophrenia and 
smoking has troubling implications. 
“Schizophrenia and smoking are considered 
complex disorders, meaning that more than one 
gene contributes to them,” says Jingchun Chen, 
an assistant professor at NIPM. “Because we 
found some genes and pathways that are shared 
between schizophrenia and smoking, we now 
believe that smoking may actually increase the 
risk of schizophrenia developing in a person 
who has these genes, so the next step is to find 
out what the function of those genes are.” 
The scientists say their work to pinpoint 
those genes could one day lead to personalized 
treatments aimed at improving patients’ quality 
SMOKE AND PEERS Xiangning Chen (right) and 
Jingchun Chen (left) look at genes to clear the air on 
the link between schizophrenia and smoking.
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of life or even preventing the condition entirely. 
The two researchers indicate that their plan to 
take advantage of the capacity of UNLV’s Cherry 
Creek II supercomputer, one of the fastest and 
most powerful supercomputers in the world, 
should enhance their ability to deliver results. 
In the meantime, they say, they’ll be looking at 
genes associated with other disorders and diseases 
to see if these might also be related to schizophre-
nia. At this point, for example, the researchers 
know that schizophrenic patients have an in-
creased chance of developing an autoimmune dis-
order—and vice versa—and are working to deter-
mine what genetic liability might link the two. 
Another project involves using Cherry Creek 
II to look for genetic ties between smoking and 
lung cancer—that is, whether a gene or set of 
genes might predispose a person to lung cancer, 
nicotine addiction, or both. Contrary to popular 
belief, Xiangning Chen says, the relationship be-
tween cigarette smoking and lung cancer is 
much more complicated.    
“Smokers that develop or die of lung cancer 
are actually the minority,” Xiangning Chen says. 
“If smoking directly caused lung cancer, you’d 
expect to see more of it.” 
Discovery of genetic roots in disease and dis-
order rests at the heart of NIPM’s mission. If re-
search can determine which genes cause a par-
ticular condition, a “personalized” treatment 
strategy can be established. This would elimi-
nate expensive guesswork associated with treat-
ments that patients may or may not respond to, 
while increasing the likelihood of an individual-
ized treatment’s success at the same time. 
“I never expect that what I do will change the 
world,” Xiangning Chen says. “But what I can do 
is give people something to think about from the 
information I can give them. If you find out you 
carry a gene that predisposes you to lung cancer, 
for example, maybe you won’t smoke. That’s 
what NIPM and researchers like me are here 
for—to try to find a way to better treat people and 
help them make more informed decisions.”
— Raegen PietRucha
A Powerful Protein
C
ell and molecular biologist Nora Caberoy 
never thought that a protein she worked 
with years ago could potentially lead to new 
discoveries in the fight against Alzheimer’s dis-
ease. But that’s exactly what the protein, called 
“tubby” because it is encoded by the TUB gene, 
may offer scientists.
It all started in 2007 while Caberoy, now an 
assistant professor in UNLV’s School of Life Sci-
ences, was working as a postdoctoral fellow at 
the Bascom Palmer Eye Institute in Miami. 
While occupied with a project related to macu-
lar degeneration—a retinal condition that 
causes a loss in central vision—she identified a 
tubby protein that is involved in the clearance of 
photoreceptor debris in the eye.
Photoreceptors are cells responsible for 
reception and processing of light as well as 
sending the signal to the brain. When old bits of 
cellular debris accumulate around the ends of 
photoreceptors, these need to be removed. 
Specialized cells make this happen, but they 
need proteins to guide the process. 
This is where tubby comes in. Tubby proteins 
bind onto cellular debris while inviting another 
type of cell, phagocytes, to begin clearing it. 
Tubby serves, in other words, as a bridge between 
the cells that need to be consumed and those that 
are supposed to eat them. 
So, what does all this have to do with Alzheim-
er’s disease? Patients with Alzheimer’s have an ac-
cumulation of amyloid beta, a protein that aggre-
gates in the brain. Caberoy says that, for reasons 
that are not entirely clear, the amyloid beta depos-
its of those with Alzheimer’s squeeze in between 
the brain cells, eventually killing them. 
“We all produce amyloid beta, but in healthy 
individuals, the production of amyloid beta is 
somehow equal to the degradation,” she says. “In 
those with Alzheimer’s, the balance is not equal.”
According to Caberoy, the body maintains 
this balance in part thanks to the work of debris- 
and pathogen-eating microglial cells that, in addi-
tion to gobbling up diseased cells, also have a 
taste for excess amyloid beta. But many scientists 
suspect that this microglial assault may have a 
serious side effect: an increase in inflammation 
that may hasten the disease’s progress and the 
subsequent death of brain cells. 
Caberoy noted from her research on photo-
receptors that the tubby protein assisted in the 
removal of damaged cells in the eye without in-
flammation. Could they perhaps be repurposed 
for use in the brain?
“We know that the active receptor in the eye 
also is present in the brain, but for some reason, it 
is not the preferred receptor,” she said. “We also 
know that the molecules that bridge that amyloid 
beta are not binding directly to the receptor.” 
In an attempt to encourage such binding, Cab-
eroy is working to create a new type of molecular 
“bridge,” one that could link amyloid beta to a less 
inflammatory protein that might neutralize it. 
In the lab, her research team undertook 
screenings to discover proteins that could bind to 
amyloid beta. They were able to identify several. 
Caberoy then “optimized” these proteins by 
mutational analysis until she found one that could 
bind to the most toxic form of amyloid beta. 
“I fused the amyloid beta binding protein to 
the part of tubby that recognizes the silent 
receptor,” she said. “Through testing, we were 
able to show that chimeric protein, which is 
created through the joining of two or more 
separate proteins, was able to bind to both the 
receptor and the amyloid beta. We also found 
that this process could reduce the production of 
inflammatory factors.” 
Over the next few months, Caberoy’s 
research team will test this process on mice with 
Alzheimer’s. She says they will first inject the 
affected mice with the chimeric protein, then 
see if it results in a reduction in the level of 
amyloid beta in the brain with the production of 
inflammatory factors in the blood. 
If successful, this process will bolster the 
patent application Caberoy has submitted for 
this method of clearing amyloid beta. 
Additionally, if the results are positive, the 
approach could eventually be used to develop 
therapies for human patients, although she 
cautions that there are still questions as to 
whether such treatment would need to be 
deployed before the disease develops or if it 
might help individuals already affected. 
Regardless, she says, there is much to be 
hopeful about.
“There could be clinical applications where 
we would produce proteins that could be inject-
ed into an individual,” she says. “You can imag-
ine someone that has a family history of Al-
zheimer’s disease taking a pill or getting an in-
jection before the disease develops.” 
— Shane Bevell
Learning From Cancer
U
NLV biochemist Ron Gary is deeply inter-
ested in physiological processes affecting 
human health, a fact that’s not immediate-
ly obvious as one gazes down at the petri dishes 
positioned around his lab. But Gary’s molecular-
level work with the cells housed in these dishes 
continues to yield important cancer-related dis-
coveries and, more recently, potentially game-
changing neuroscientific findings related to Al-
zheimer’s disease. 
The Alzheimer’s discoveries were an out-
growth of the cancer research. Gary and his labo-
ratory team were working to learn whether in-
hibiting the aberrant activity of a particular “sig-
naling” enzyme, glycogen synthase kinase-3 
(GSK-3), might slow the explosive growth of 
cancer cells. Because the enzyme has also been 
implicated in the development of Alzheimer’s, 
Gary’s team soon found themselves thinking 
about the ways in which inhibiting GSK-3 might 
affect a key component of that disease as well.
There are two microscopic structures that 
are characteristically found in the brains of 
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Alzheimer’s patients: plaques and neurofibrillary 
“tangles.” At the molecular level, neurofibrillary 
tangles are perhaps the illness’s most 
distinguishing feature. The tangles are composed 
of tau—proteins that, when working normally, 
play a key role in transporting nutrients and 
other important materials throughout the cell. 
When tau proteins aggregate in the brain and 
form tangled clumps, the transportation system 
breaks down, cells begin to die, and Alzheimer’s 
symptoms appear. 
Gary, a professor in UNLV’s Department of 
Chemistry and Biochemistry, suspects that 
GSK-3 may be inadvertently inducing tau tan-
gling by accelerating a process called phosphor-
ylation—a crucial metabolic step by which, 
under normal circumstances, cells regulate 
various molecular processes.
“Though we don’t know why it becomes 
overactive and produces tangled tau, our think-
ing is that, if you could suppress or slow that 
phosphorylation activity of GSK-3, you could 
stop or slow the formation of tau tangles,” Gary 
says. “Then maybe you could prevent or slow the 
progression of Alzheimer’s.” 
In order to reduce GSK-3 and suppress the 
formation of tangles, Gary says, researchers 
would need to develop an inhibitor, a compound 
or drug that would depress its activity. Gary and 
his team of students are working to do just that. 
“We take human cells of brain origin, treat 
them with different drugs in a dish, and look at 
the molecular consequences of that treatment,” he 
said. “You can’t just eliminate the GSK-3 enzyme, 
because that would be problematic as well.”
Gary says a handful of key questions are 
guiding his lab team’s efforts. What are the con-
sequences more broadly throughout the cell, 
and specifically, do different types of inhibitors 
do the same thing throughout the different ar-
eas where GSK-3 has a function? Or could differ-
ent inhibitors have subtly different effects on 
GSK-3-related systems? 
Gary says he’s also interested in examining 
beta-catenin, another important molecule influ-
enced by GSK-3. Beta-catenin plays a crucial role in 
the control of cell growth. If out of balance, it could 
potentially be a contributing cause of cancer. 
According to Gary, when you inhibit GSK-3 
with the goal of reducing tau tangles, it seems 
likely you would also reduce the phosphoryla-
tion of beta-catenin. 
“You would initially assume that any 
inhibitor that suppresses GSK-3 enzyme 
activity would have a similar effect on beta-
catenin, but we found that different inhibitors 
have different effects on beta-catenin,” he 
says. “This is important because Alzheimer’s 
work covers everything from treating patients 
to the other end of the spectrum, looking at 
molecular effects in isolated cells. But if we 
ever want to use this class of compound to 
treat patients, we would want to know what 
else happens in the cell when you suppress 
tau phosphorylation by inhibiting GSK-3.” 
— Shane Bevell
Treatments in Balance
M
uch like other parents, Merrill Landers, a 
father of four who chairs UNLV’s Depart-
ment of Physical Therapy, often admon-
ishes his children to go outside and play. Some-
times, he admits, he does this so that he and his 
wife have a moment’s peace. More often, he 
says, it’s to encourage his children to be more 
physically active. Landers knows that outdoor 
activities such as running around in the yard, 
kicking a soccer ball, or riding a bicycle are cru-
cial to the growth and development of healthy 
young bodies.
And that may not be the only benefit. Accord-
ing to recent research findings, Landers indicated, 
an accumulation of steady physical activity dur-
ing our youth and college years may generate a 
protective effect in the brain—one that could re-
duce the risk of, or even prevent, neurodegenera-
tive diseases like Parkinson’s disease.
Landers’ research has focused on Parkin-
son’s disease since he joined the UNLV faculty 
in 2001. His recent work involves examining 
how exercise might influence the disease’s 
“There could be clinical applications where we would produce [tubby] proteins that could be injected into an individual,” says Caberoy. “You can imagine 
someone that has a family history of Alzheimer’s disease taking a pill or getting an injection before the disease develops.”
EYES WIDE OPEN 
Nora Caberoy 
discovered that her 
research on proteins 
in the eye might 
someday help us 
fight Alzheimer’s.
DOUBLE TROUBLE 
Ron Gary’s enzyme 
research serves two 
purposes; cancer and 
Alzheimer’s, beware.
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course and determining whether patients’ 
physical activity might improve their balance 
and walking—work that has neatly segued into 
a broader set of findings on activity and neuro-
degenerative protective effects within the field, 
he indicated. 
The four cardinal signs in Parkinson’s dis-
ease, Landers says, are bradykinesia (slowness of 
movement), rigidity, resting tremors, and pos-
tural instability (poor balance). The first three 
respond to and can be improved with medica-
tion. Postural instability does not respond to Par-
kinson’s disease medications; the only treatment 
approach that has been demonstrated to be ben-
eficial is balance training.
“Falling represents one of the two leading 
causes of premature death among people with 
Parkinson’s disease,” says Landers. “The first is 
aspiration pneumonia. Falling can cause the 
domino effect of fractures to surgery to postop-
erative complications to other falls. For me, pre-
venting falls is a big issue.”
One aspect of Parkinson’s disease that 
piques Landers’ curiosity is how falls affect peo-
ple with the disease. Healthy adults typically 
evaluate the circumstances of a fall in two ways. 
If it’s a fluke, they forget about it. If there is a 
reasonable chance the fall could happen again, 
they seek ways to prevent future tumbles.
For people with Parkinson’s disease, it’s 
more complicated. A fall may cause anxiety or 
fear, emotions that may result in an unhealthy 
avoidance of normal activities. They may limit 
visits to friends, attending church, or venturing 
out in public. Some become reclusive, a condi-
tion that can initiate a spiral of declining 
health. When fall-averse people with Parkin-
son’s disease seldom leave their homes, they 
tend to lose strength, coordination, and bal-
ance. These deficits, in a cruel irony, make them 
more susceptible to falling in their homes as 
they move from room to room.
“Some level of fear is good and can be pro-
tective, but too much can become harmful, espe-
cially in this disease population,” says Landers. 
“Those who shouldn’t be going out can be 
coached to become more careful and trained to 
improve their balance. Those who have high lev-
els of fear need additional help.”
During a study involving older adults, Land-
ers first measured “balance characteristics,” or 
participants’ ability to balance, while asking 
them to self-report their “balance confidence.” 
He followed the study participants for one year, 
noting when and how often they fell. The results 
indicated the self-assessments were the best pre-
dictors of future falls. The next best predictor 
was fall-avoidance behavior.
Using data obtained from another study, 
Landers helped rebuild the confidence of 
those who reported lower levels of balance 
and stability. Balance training became a key 
prescription. 
As with his own children, Landers says, adults 
need exercise to maintain and strengthen muscles. 
Most people with Parkinson’s disease are 
prescribed a regimen of low-intensity exercise—a 
level so low, Landers says, it’s ridiculous.
“When we look at someone with Parkinson’s 
disease and see the poor posture and the slow 
movements, we assume he or she can’t handle 
exercise. I think this is a big misconception and 
became something I wanted to test.”
In 2015, Landers led an “exercise boot camp” 
study to evaluate the ability of people with Par-
kinson’s to handle high-intensity exercise, which 
comprised three components: strength exercises 
at greater than 70 percent of the person’s one-
repetition maximum, endurance exercises at 70 
to 75 percent of the person’s estimated maxi-
mum heart rate, and exercises using dynamic 
and challenging balance-coordination tasks.
The results were clear: Those with high-inten-
sity workouts responded well to the increased level 
of activity, and they did not experience more falls 
than the low-intensity group. What’s more, they 
enjoyed it—even more so than the low-intensity 
group enjoyed their activity.
Landers next sought to determine whether 
such intense exercise might act as an inhibitor of 
the disease’s progression. Many studies among 
laboratory animals had previously indicated that 
exercise can protect the brain from the disease. 
Some of the results even showed small animals 
actually recovering from the disease. 
Landers then found results from five or six 
studies that indicated exercise during a person’s 
early adult life could have a cumulative effect 
and protect against the disease—that is, the risk 
“Falling represents one of the two leading causes of premature death among people with Parkinson’s disease,” says Merrill Landers. “Falling can cause the 
domino effect of fractures to surgery to postoperative complications to other falls. For me, preventing falls is a big issue.”
CURRENT AFFAIRS 
Brach Poston’s 
research on 
electrical stimulation 
shows promise for 
Parkinson’s patients. 
BALANCING 
ACT Physical 
activity can help 
protect us from 
Parkinson’s, Merrill 
Landers says. 
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for Parkinson’s decreased with an increase in 
physical activity in early adult life. Those results, 
he says, stimulated his curiosity further.
“As scientists, we know exercise benefits 
many different body systems, but the evidence 
strongly suggests that exercise also benefits our 
brains,” Landers says. “Physiologically, exercise 
—particularly aerobic exercise—increases a 
chemical called brain-derived neurotrophic 
factor, or BDNF, which stimulates neuronal 
growth and helps potentiate neuroplasticity. 
“BDNF is present when the brain learns a 
new skill or motor task. It also protects neu-
rons, including the dopaminergic neurons that 
are affected by PD. So, presumably, having 
greater quantities of BDNF will protect more of 
those neurons, thereby slowing the progression 
of the disease.”
Landers and his team are currently exploring 
how BDNF (known to increase with aerobic exer-
cise) and anti-inflammatory enzymes influence 
disease progression and response to exercise, and 
whether the successes with laboratory animals 
might apply to human beings. If successful, the 
study could further validate exercise as a neuropro-
tective strategy against Parkinson’s disease, either 
preventing its onset or slowing its progression.
Landers plans to present his findings during 
the World Parkinson Congress in Portland, Ore-
gon, this October. He hopes his results will help 
convince those working with Parkinson’s patients 
that high-intensity exercise is not only safe but 
more effective than low-intensity workouts.
In the future, Landers says his plans include 
studying the effects of exercise during midlife 
and later. He’ll also explore related genetic infor-
mation, which might allow scientists to gain ad-
ditional insights into gait and balance function 
in those with Parkinson’s disease. 
As for his children, Landers expects them to 
make exercise a regular part of their lives. And 
he plans to join them.
— Kevin Dunegan
Stimulating Parkinson’s Research
U
NLV’s Brach Poston is exploring how low 
levels of electrical stimulation may con-
tribute to improved motor performance in 
people with neurodegenerative diseases such as 
Parkinson’s disease.
And how did he choose this scientific path? 
Foresight.
After earning a master’s degree in exercise 
physiology from UNLV and a doctorate at the 
University of Colorado, Boulder, Poston began 
a postdoctoral program at Arizona State Uni-
versity. There he learned about brain stimula-
tion, immediately recognizing its potential as 
the next “big thing” in his field.
“I was introduced to the methods of 
transcranial magnetic stimulation [TMS] and 
transcranial direct current brain stimulation 
[tDCS],” Poston says. “I saw tDCS as a 
promising [way] to help people, and I was 
fortunate enough to be admitted to a postdoc 
program at the National Institutes of Health 
[NIH], where I was able to learn about this 
type of stimulation.” 
Poston spent the next year and a half study-
ing how to use multiple noninvasive brain-
stimulation techniques. After reviewing stud-
ies from other scientists, he became convinced 
that, as he puts it, “tDCS was most likely to be 
the best noninvasive stimulation option for 
aiding those with Parkinson’s disease.”
Parkinson’s is a disease of the basal ganglia, 
an area of the brain that is vital to motor con-
trol and the production of dopamine. Dopa-
mine is more known for its involvement in re-
ward mechanisms and reinforcement learning 
in the brain, but it also plays a crucial role in 
mobility. When a person completes a complex 
movement, action, or task, dopamine is re-
quired to enable the basal ganglia to assist his 
or her motor cortex with movement planning, 
execution, and learning. 
When using tDCS to treat Parkinson’s pa-
tients, clinicians connect saline-soaked sponges 
to rubber electrodes that are distributed across 
the scalp. They then pass a weak electric cur-
rent from one electrode to the other. The idea is 
to use the current to excite or inhibit activities 
that are thought to originate in specific areas of 
the brain. For Parkinson’s disease patients, 
these areas often include the motor cortex, a 
part of the brain’s cerebral cortex associated 
with muscular activity.
Preliminary findings by Poston and others 
have shown promise: tDSC does appear, in fact, 
to improve performance of simple motor tasks 
performed by hands and arms. These tasks can 
include using a pinch-grip movement to gener-
ate force against an object, retrieving small ob-
jects like buttons or coins, or performing an 
arm movement to a target.
The electric current doesn’t cause the ac-
tion to happen, Poston explains; it simply aug-
ments the normal increase in the “excitability 
of cortical neurons” when a task is practiced. 
When someone wants to lift an object—pick-
ing up a glass, for example—cortical neurons 
become excitable and act to execute that move-
ment. When you practice a particular action, 
such as throwing a ball, the neurons become 
more excitable over time. This leads to im-
proved accuracy and efficiency of movement.
The lower levels of dopamine common 
among Parkinson’s patients cause impairments 
in the communication between the basal gan-
glia and the motor cortex, a breakdown that 
reduces cortical neurons’ excitability during 
movement  execut ion—thus  the  s lower 
movements, reduced muscle activity, and less 
a c cu ra t e  movement s  expe r i enced  by 
Parkinson’s disease patients. By augmenting 
excitability among cortical neurons when tasks 
are being attempted, tDCS boosts motor con-
trol in the short term. 
Although tDCS today is used only on outer 
areas of the brain, Poston believes—based on 
study results involving animal models—the 
technique might one day be used to elicit ef-
fects within deeper brain structures. 
Poston’s first studies at UNLV sought to 
identify the optimal method for one-time tDCS 
treatment among people with the disease. His 
findings helped identify optimal placements of 
electrodes, correct electric current strengths, 
and optimal durations for stimulation.  
With these parameters established, Poston 
moved on to explore using daily stimulation to 
treat patients during a two-week period. “During 
a single treatment, we and other research groups 
have typically seen a 10 to 15 percent perfor-
mance improvement, with the effects lasting up 
to 90 minutes,” he says. “Daily application could 
produce a cumulative effect, and we hope to be 
able to elicit performance improvements of ap-
proximately 30 percent, which were seen in 
studies among young adults, when we apply 
stimulation over a two-week period.”
Poston also broke some new ground last 
summer by using tDCS on the cerebellum. This 
hasn’t been done in Parkinson’s disease before 
but has been shown to increase motor perfor-
mance in both younger and older adults. The 
rationale for this is that, because the cerebel-
lum has been shown to compensate for im-
paired basal ganglia activity in Parkinson’s dis-
ease, applying tDCS to excite the cerebellum 
may enhance this compensation. 
Poston’s previous and current studies focus 
exclusively on the hands and arms, but he says 
he now has the funding that will enable him to 
test tDCS while a person is walking. Doing this 
will involve Parkinson’s disease patients walk-
ing on a treadmill. The goal is to determine 
how tDCS treatments affect patients’ stride 
length, velocity, and movement variability. 
So far, Poston says his results are positive 
and that, in the future, he expects the treatment 
to become a more widely used adjunctive ther-
apy. He also says that affordable, wearable 
tDCS devices have a realistic potential to be-
come available for home use, a place where pa-
tients or caregivers could easily apply the stim-
ulation as needed.
— Kevin Dunegan
